Vanda Pharma’s Investigastional Insomnia Agent VEC-162, Demonstrated Favorable Results in Phase II Study
"We are encouraged by these clinical results," said Mihael Polymeropoulos, MD, CEO of Vanda, "which demonstrate that, in VEC-162, we may have the first therapy available to treat the millions of patients who suffer from the consequences of a misalignment of their sleep/wake cycle." Treatment with VEC-162 was generally well tolerated in the study with the adverse events mild to moderate in nature.
Results of the study were presented at the SLEEP 20th Anniversary Meeting of the Associated Professional Sleep Societies (APSS) by Dr. Shantha M.W. Rajaratnam, Division of Sleep Medicine, Brigham and Women's Hospital, Harvard Medical School.
Source: Vanda Pharmaceuticals Inc.
Comment Preview